Intracranial aneurysms treated with pCONus hydrophilic polymer coating (HPC) device: clinical and anatomical findings in 15 patients
| Patient | Hunt and Hess | Fisher score | Aneurysm location | Neck width (mm) | Dome width (mm) | EVD | Medication before treatment (IV ASA) | Multiplate (ASPI)/VerifyNow (ARU) before treatment | Postmedication - from day 1 after treatment (IV ASA) | pCONUS HPC | Complications | Immediate mRRC | FU (months) | mRRC at FU | Final mRS score |
| 1 | II | IV | BA | 3.8 | 4.5 | Y – pre | 1×500 mg | 37 U / 422 | 1×100 mg | pCONUS1 - 3-20-4 | – | I | Dead | Dead | 6 |
| 2 | I | III | MCA | 6.5 | 7 | N | 1×500 mg | 10 U / 420 | 1×100 mg | pCONUS2 - 4-15-8 | Stroke | II | 2 | IIIb | 0 |
| 3 | IV | IV | AcomA | 5.4 | 8.1 | Y – pre bilateral | 1×500 mg | 23 U / 413 | 1×500 mg | pCONUS2 - 4-15-6 | – | II | 8,7 | II | 4 |
| 4 | II | III | MCA | 5 | 18 | N | 2×500 mg | 7 U / 452 | 2×500 mg | pCONUS2 - 4-15-6 | – | II | 4,3 | II | 1 |
| 5 | II | III | AcomA | 8.3 | 12 | Y – pre | 1×500 mg | 55 U / 447 | 1×500 mg | pCONUS2 - 4-15-10 | – | II | 6,7 | II | 3 |
| 6 | III | IV | AcomA | 4.6 | 6 | N | 1×500 mg | 20 U / 402 | 1×500 mg | pCONUS2 - 4-15-6 | – | II | 9,1 | IIIa | 5 |
| 7 | IV | IV | MCA | 4.5 | 5 | Y – pre | 1×500 mg | 24 U / 428 | 2×500 mg | pCONUS1 - 4-20-5 | – | IIIa | Not yet | Not yet | N/A |
| 8 | III | II | MCA | 4.7 | 12 | N | 2×500 mg | 2 U / 478 | 1×500 mg | pCONUS2 - 4-15-6 | Thrombus formation | II | 3,4 | II | 1 |
| 9 | V | IV | MCA | 6.5 | 8 | Y – pre | 1×500 mg | 14 U / 446 | 1×500 mg | pCONUS2 - 4-15-8 | – | IIIa | 0,7 | IIIb | 2 |
| 10 | V | IV | AcomA | 4.7 | 4.6 | Y – pre | 1×500 mg | 15 U / 562 | 1×500 mg | pCONUS1 - 4-20-5 | Thrombus formation | II | 5,6 | II | 0 |
| 11 | V | IV | ICA | 6.7 | 24.2 | Y – pre | 2×500 mg | 14 U / 415 | 2×500 mg | pCONUS2 - 4-15-10 | ICA dissection | IIIa | 7,9 | IIIa | 3 |
| 12 | IV | IV | AcomA | 7 | 13.8 | Y – pre | 2×500 mg | 20 U / 404 | 2×500 mg | pCONUS2 - 4-15-15 | – | II | 5,4 | IIIa | 5 |
| 13 | II | I | BA | 8.7 | 10 | N | 1×500 mg | 18 U / 502 | 2×500 mg | pCONUS2 - 4-15-10 | – | IIIa | 3 | IIIb | 1 |
| 14 | III | III | PcomA | 9.8 | 13 | N | 2×500 mg | 21 U / 402 | 2×500 mg | pCONUS2 - 4-15-15 | – | IIIb | Not yet | Not yet | N/A |
| 15 | V | IV | AcomA | 6 | 3.5 | Y – pre | 2×500 mg | 18 U / 469 | 2×500 mg | pCONUS2 - 4-15-6 | Thrombus formation | I | Not yet | Not yet | N/A |
AcomA, anterior communicating artery; ARU, aspirin reaction units; ASA, acetylsalicylic acid; ASPI, acetylsalicylic platelet inhibitor; BA, basilar artery; EVD, external ventricular drainage; FU, follow-up; ICA, internal carotid artery; IV, intravenously; MCA, middle cerebral artery; mRRC, modified Raymond-Roy classification; mRS, modified Rankin Scale; N/A, non-available; PcomA, posterior communicating artery.